It's good news for Migraine patients as Eli Lilly and Company's Emgality™ (galcanezumab-gnlm) became the third new CGRP monoclonal antibody approved by the FDA for Migraine Prevention in Adults. With Emgality™ approved for Migraine prevention, patients have choices of preventive treatments were developed specifically for Migraine.
NIH awards grant to CerSci Therapeutics for a preclinical trial to explore the development of a potentially new Migraine treatment blocking the free radical, peroxynitrite. This is just the first of many new studies we can expect as researchers work to develop better, safer treatments for Migraine.
Out of My Head shows what Migraine is and it's impact from a variety of perspectives — the Migraine patient, family members, physicians, researchers, and more. It's honest and really hits home. For people with Migraine, Out of My Head is validating. For people who don't have Migraine, it can be exceptionally illuminating and educational.
This is a transcript of an interview with Dr. Peter Goadsby. I had the privilege of meeting with him in San Francisco at the June 2018 AHS Scientific Meeting. In the interview, we discussed the recent results of the Autonomic Technologies CH-2 clinical trial of their sphenopalatine ganglion microstimulator system.